PT-141 (Bremelanotide): What the Evidence Shows
Bremelanotide (Vyleesi) is FDA-approved for one specific group of women. The benefit is real but modest, nausea is common, and "PT-141" sold as a research peptide is a different story.
PT-141 is the research name for bremelanotide, a peptide sold under the brand name Vyleesi. In June 2019, the U.S. Food and Drug Administration (FDA) approved it as the first on-demand treatment specifically for premenopausal women with a condition called acquired, generalized hypoactive sexual desire disorder, or HSDD. The drug's official label lists an initial U.S. approval of 2019. Because the same molecule circulates online as an unregulated "research peptide," it helps to separate what the human evidence actually supports from what it does not.
Below is a plain-language look at how the drug works, what the trials found, who it is and is not for, and where the evidence is genuinely thin. The short version: for a narrowly defined group, the benefit is real but small, and the side effects are common enough to be the main practical limitation.
How it works
Bremelanotide is a synthetic cyclic peptide that activates melanocortin receptors in the body, mainly the melanocortin-4 receptor (MC4R), and also MC1R. According to an NIH monograph, it acts centrally in the brain rather than on blood vessels or genital tissue. That is what sets it apart from erectile-dysfunction drugs such as sildenafil, which work on blood flow.
There is direct human evidence for this brain-based mechanism. In a functional-MRI study of 31 premenopausal women with HSDD, activating MC4R with bremelanotide changed how the brain processed erotic images: it increased connectivity between the amygdala and insula relative to placebo, and reduced activity in a self-monitoring brain region (the secondary somatosensory cortex). More women reported increased sexual desire after the drug than after placebo (P = 0.007). It is a small, mechanistic study, but it supports the idea that the effect is central rather than peripheral.
What the trials actually show
The approval rests on two identical Phase 3 trials known as the RECONNECT studies (Study 301 and Study 302). Each ran 24 weeks and was randomized, double-blind, and placebo-controlled. Together they enrolled a solid, adequately powered group: 1,267 premenopausal women randomized, with 1,247 in the safety population, all with acquired, generalized HSDD. Participants used the drug on an as-needed basis.
In the pooled results, women on bremelanotide showed a statistically significant improvement over placebo, but the size of the improvement was modest. Desire rose by an integrated FSFI-desire change of +0.35 (P < .001) on a scale that runs roughly from 1.2 to 6.0, and desire-related distress fell by an integrated FSDS-DAO item-13 change of -0.33 (P < .001). Statistically clear; numerically small.
The benefit is statistically real but modest. Bremelanotide is not a large-effect aphrodisiac.
Independent reviewers have pushed on exactly this point. They have questioned how clinically meaningful the change is, whether the rating scales used were the right ones, and whether the effect sizes matter in daily life, concluding that the benefits may only be modest. It is also worth noting what the trials did not do: they compared the drug against placebo, not against the other approved HSDD medication (flibanserin) or against non-drug approaches. There is no head-to-head evidence.
Side effects and safety
Tolerability is the main practical limit. The most common side effects reported in the trials were:
- Nausea, in 40% of treated patients, usually worst with the first dose. Anti-nausea medication was needed in 13%, and 8% dropped out of the trials because of it.
- Flushing, in 20% (versus under 1% on placebo).
- Headache, in 11% (versus 2% on placebo).
- Focal hyperpigmentation, in about 1%darkening of skin or gums, including the face, gingiva, and breasts. It may not fully resolve, and the risk is higher with darker skin and more frequent dosing.
The drug also transiently raises blood pressure (peak increases of roughly 6 mmHg systolic and 3 mmHg diastolic) and lowers heart rate after each dose, generally returning to baseline within 12 hours. Because of this, the label makes cardiovascular caution explicit: it is contraindicated in uncontrolled high blood pressure or known cardiovascular disease, and it is not recommended for people at high cardiovascular risk. NIH's LiverTox has also noted rare cases of drug-induced liver injury.
The approved product is a subcutaneous auto-injector delivering 1.75 mg, given at least 45 minutes before anticipated sexual activity. Dosing is capped at one dose per 24 hours and no more than 8 doses per month, and the label directs stopping after 8 weeks if symptoms do not improve. An earlier intranasal (nasal spray) version was abandoned during development: after the FDA halted Phase II trials in 2007 over blood-pressure increases, the manufacturer ceased nasal-spray development in 2008.
Who it is (and isn't) for
The human efficacy data and the FDA approval cover only one group: premenopausal women with acquired, generalized HSDD that is not caused by another medical or psychiatric condition, relationship problems, or medications. The label is explicit about the boundaries. Bremelanotide is not indicated for HSDD in postmenopausal women, is not FDA-approved for men, and is not indicated to enhance sexual performance.
This matters because the same peptide, labeled "PT-141," is widely sold as a research chemical or through gray-market and compounding vendors, often with claims about boosting libido in men or in the general population. Those claims are not established by the trials described here. The human trial evidence applies only to the regulated, standardized product.
The bottom line
For premenopausal women with acquired, generalized HSDD, bremelanotide offers a real but modest improvement in desire and distress, backed by two adequately powered trials and a plausible brain-based mechanism. Against that, nausea is common, the on-demand timing (45-plus minutes before sex) is impractical for many, and independent reviewers doubt how meaningful the average benefit is. Outside that specific group, and especially for unregulated "PT-141," the evidence simply does not exist. Anyone considering it should weigh those trade-offs with a licensed healthcare professional.
- 01 FDA Prescribing Information for VYLEESI (DailyMed / NLM), 2019 dailymed.nlm.nih.gov ↗Official label: 2019 approval, indication and limits, side-effect rates, blood-pressure and hyperpigmentation warnings, dosing.
- 02 LiverTox, NIDDK (NIH/NCBI Bookshelf), 2021 ncbi.nlm.nih.gov ↗NIH monograph on bremelanotide's melanocortin-receptor (MC4R/MC1R) central mechanism and rare liver injury.
- 03 Thurston et al., Journal of Clinical Investigation (NIH PMC), 2022 pmc.ncbi.nlm.nih.gov ↗Functional-MRI crossover study in 31 premenopausal women with HSDD showing central, brain-based mechanism; more women reported increased desire on drug vs placebo (P=0.007).
- 04 Kingsberg, Clayton, Simon et al., Obstetrics & Gynecology (PubMed), 2019 pubmed.ncbi.nlm.nih.gov ↗Pooled RECONNECT Phase 3 trials (1,267 randomized; 1,247 safety population); integrated FSFI-desire +0.35 and FSDS-DAO item-13 -0.33 versus placebo (both P<.001).
- 05 Bremelanotide, Wikipedia, 2026 en.wikipedia.org ↗Tertiary source used for approval date, abandoned nasal-spray development history, and the characterization that reviewers consider benefits modest.
Wellness Wire Editorial
The Wellness Wire editorial team. Our explainers are researched from primary sources — clinical-trial reports and FDA labeling — and written for general education. They are not individually reviewed by a clinician and are not a substitute for medical advice.
